Why patients ask about NAD+
Walk into almost any wellness clinic today and you will find an IV drip menu with a NAD+ infusion listed somewhere between the vitamin C push and the myers cocktail, priced anywhere from $500 to $1,500 per session. Walk into any pharmacy or open any supplement website and you will find bottles of NMN and NR capsules marketed with the same word attached to all of it: longevity. The marketing has outrun the biology here, and I want to spend this article separating the two.
NAD+ — nicotinamide adenine dinucleotide — is a real and important molecule. It is a redox cofactor required for hundreds of enzymatic reactions in the body, including the sirtuins, PARPs, and CD38 enzymes that govern mitochondrial energy production, DNA repair, and cellular stress response. NAD+ levels do fall measurably with age in multiple tissues, and that decline is a legitimate, well-documented piece of aging biology. This mechanistic fact is the hook that drives the entire NAD+ longevity narrative, and it is not wrong as biology.
Where I want to be careful is the leap from that mechanistic fact to a clinical recommendation. The honest clinical question is not “can we raise NAD+ levels?” — we clearly can, through more than one route. The honest question is: does raising NAD+ do anything measurable for the patient in front of me — more energy, better cognition, improved function, a favorable shift in an aging biomarker that predicts something real? That is a different, harder, and much less settled question, and it is the one this article is actually about.
Three ways people are actually raising NAD+ today
Setting aside marketing claims, there are exactly three routes patients are using in practice, and each has a meaningfully different evidence base, dosing history, and regulatory status.
Oral NR (nicotinamide riboside) is typically dosed at 300–2,000 mg per day. It is the most-studied precursor by trial count, it was accepted by the FDA as a New Dietary Ingredient (NDI 882), and its regulatory path has been uneventful compared to its counterpart.
Oral NMN (nicotinamide mononucleotide) is typically dosed at 250–900 mg per day. Its regulatory history has been turbulent: the FDA excluded NMN from the dietary supplement definition in November 2022, citing a pharmaceutical company's prior IND filing for MIB-626, a purified NMN formulation. The FDA reversed that determination on September 29, 2025, and NMN is again lawful as a dietary supplement.
IV NAD+ is delivered as a direct infusion, typically 250–750 mg over 2–4 hours. It is not FDA-approved for any indication, has no established therapeutic protocol, and is delivered as a wellness or compounded intervention rather than a regulated drug.
What actually happens to your NAD+ on each route
This is the section that matters most clinically, because the honest answer is different for each of the three routes — and, as you will see, the strength of the underlying evidence is not evenly distributed.
Oral NR — the most-studied precursor
The first human trial of NR, Trammell et al. 2016, gave single doses of 100, 300, and 1,000 mg and found a dose-dependent increase in the NAD+ metabolome with no serious adverse effects — a reassuring first signal.
The strongest single controlled trial is the Martens et al. 2018 crossover trial in healthy middle-aged and older adults: a six-week crossover in 30 healthy adults aged 55–79, in which 1,000 mg/day NR was safe, well tolerated, and stimulated NAD+ metabolism, with signals of reduced systolic blood pressure and aortic stiffness in the stage 1 hypertensive subgroup. Conze et al. 2019 found that 300 mg or 1,000 mg of NR daily significantly increased whole blood NAD+ within just one week.
The Orr et al. 2024 NR pilot RCT in older adults with MCI produced the headline number in this article's stat row: a 2.6-fold increase in blood NAD+ at the target dose, with no between-group difference in adverse events — a reassuring safety signal in a more vulnerable population. On the higher-dose end, the NR-SAFE 2023 high-dose trial in Parkinson's disease found up to a five-fold NAD+ increase, with a mild, transient homocysteine elevation and no serious safety signal.
The trial I think every patient asking about NR should hear about is the NICE 2024 peripheral artery disease RCT in Nature Communications: 90 patients randomized to NR (with or without resveratrol) versus placebo. NAD+ rose as expected. Six-minute walk distance — the actual functional outcome that mattered to these patients — did not improve versus placebo at six months. This is the clearest published example of the exact gap this whole article is about: the biomarker moved, the outcome did not.
Oral NMN
The early positive signal for NMN comes from Yoshino and Imai's 2021 trial in postmenopausal women with prediabetes, where oral NMN improved muscle insulin sensitivity — a genuinely encouraging early result, though a single trial in a specific population.
Safety data has been consistently reassuring: Yamane et al. 2022 found 12 weeks of 250 mg/day NMN in healthy volunteers was safe with no clinically meaningful adverse effects, and Kim et al. 2022 in npj Aging found that 250 mg/day for 6 or 12 weeks in aged men increased whole blood NAD+ and NAD+ metabolites and was well tolerated.
The result I lead with when a patient asks me about NMN, however, is the 2024 NMN systematic review and meta-analysis in Critical Reviews in Food Science and Nutrition: NMN reliably raises blood NAD+ across pooled trials, but most clinically relevant outcomes did not differ significantly from placebo, and the authors explicitly note that “an exaggeration of benefits may exist in the field.” That is about as direct a caution as you will see in a peer-reviewed meta-analysis. Consistent with this, the pharmaceutical formulation MIB-626 raised NAD+ but did not improve exercise capacity in a phase 2 trial.
The only published human pharmacokinetic study of IV NAD+, Grant and colleagues 2019 pilot pharmacokinetic study of a 6-hour IV NAD+ infusion, infused NAD+ over six hours in eight subjects. Plasma NAD+ was undetectable for the first two hours — indicating rapid extraction from circulation — then rose roughly 398% by hour six. The metabolome showed conversion to nicotinamide and downstream metabolites, meaning the intact NAD+ molecule itself does not persist in circulation for long; what is measured later is partly its breakdown products. A 2024 pilot comparison, Hawkins and Idoine's 2024 real-world pilot comparing commercial NAD+ IV against NR IV, found that NR delivered intravenously produced larger, more sustained NAD+ increases with fewer adverse events and a 60% shorter infusion time than NAD+ itself. Most importantly: there are zero published randomized controlled trials comparing IV NAD+ to placebo on any clinical outcome — not fatigue, not cognition, not exercise capacity, not any aging biomarker. Every claim you hear about how IV NAD+ makes patients feel is anecdotal until that trial exists.
“Every route we have discussed can raise a number on a lab report. Only one of them — oral NR — has been tested against placebo on an actual functional outcome, and in the one trial that did this well, the outcome did not move.”
The side-effect profile nobody advertises
IV NAD+ commonly causes chest tightness, flushing, nausea, and abdominal cramping during the infusion, along with a pounding or racing sensation — which is exactly why clinics slow the drip to 2–4 hours rather than pushing it faster. IV access itself carries the ordinary risks of any infusion: phlebitis, infiltration, and infection at the site.
Oral NR and NMN have a materially milder profile. Across more than 500 trial participants pooled from the studies above, adverse events run 5–12% and are almost entirely mild gastrointestinal complaints — nausea, bloating, loose stools — plus occasional transient headache or flushing, generally resolving within a week. No trial has reported hepatotoxicity, nephrotoxicity, or a serious cardiovascular signal from either oral precursor.
The honest caveat that applies to every route equally: long-term safety data beyond 12 months does not exist for IV NAD+, oral NR, or oral NMN. Everything we know comes from trials measured in weeks to a small number of months.
The regulatory picture as of July 2026
Physicians recommending or discussing any of these three routes need to know exactly where each one stands with the FDA, because the regulatory story has moved substantially even in the past year.
| Route | Regulatory status (July 2026) | Key detail |
|---|---|---|
| Oral NR | Lawful dietary supplement | NDI 882 accepted by FDA; GRAS letter for use in food/beverage up to 300 mg/serving |
| Oral NMN | Lawful dietary supplement again as of Sept 29, 2025 | FDA reversed its Nov 2022 drug-preclusion determination after an NPA lawsuit and citizen petition; December 2025 confirmation letters to SyncoZymes and Inner Mongolia Kingdomway reinstated NDI status |
| IV NAD+ | Not FDA-approved for any indication | Typically administered via 503A/503B compounding pharmacies; use is off-label/experimental with no established evidence-based protocol |
The NMN reversal is worth a beat of its own detail because so many patients still believe it is illegal. The FDA's original November 2022 position treated NMN as excluded from the supplement definition because a company had already filed an investigational new drug application for MIB-626, a purified NMN formulation, before NMN was marketed as a supplement — a legal mechanism, not a safety finding. The Natural Products Association's account of the FDA's 2025 NMN reinstatement and independent trade coverage from NutraIngredients' 2025 report on the FDA's NDI status reinstatement for NMN both confirm the reversal took effect September 29, 2025, with formal NDI confirmation letters following that December. NMN is, again, a lawful dietary supplement.
What I actually tell patients at Pravida
If a patient wants to raise NAD+ and is otherwise an appropriate candidate, oral NR — or oral NMN, given the regulatory reversal — at the doses studied in the trials above is where the actual data is. That is not an enthusiastic endorsement of outcome benefit; it is an honest statement of where the evidence currently sits relative to the alternative.
I do not recommend routine IV NAD+ for fatigue, “brain fog,” or generic anti-aging goals, because the outcome evidence is not there — the marketing is. That distinction matters, and I say it directly to patients rather than softening it.
I do consider IV NAD+ in select circumstances: a patient who has genuinely failed an adequate trial of oral precursors, has a specific clinical rationale for wanting the IV route, understands the evidence gap described in this article, and can tolerate the infusion side-effect profile. That is a narrow set of patients, and I want them to make that decision with full information, not clinic marketing.
The heavier lifters for NAD+ preservation remain the unglamorous, well-established interventions: 7–9 hours of sleep, resistance training, an aerobic base, adequate protein intake, avoiding chronic alcohol use, and treating obstructive sleep apnea if it is present. None of these will be sold to you in a $1,000 infusion, and all of them have more total evidence behind their value than any NAD+ precursor does.
What I want to see before I change my practice
There are four things I am watching for before my recommendations here shift meaningfully. First, randomized placebo-controlled outcome trials of IV NAD+ — not just surrogate NAD+ blood levels, but a real functional or symptomatic endpoint. Second, head-to-head trials of IV NAD+ against high-dose oral NR or NMN on validated fatigue, cognitive, and functional endpoints, so patients and physicians can actually compare routes rather than guess. Third, tissue-level NAD+ measurements rather than blood alone, since the entire biological rationale is intracellular cofactor availability, and blood is a proxy at best. Fourth, long-term safety data beyond 12 months at the doses being used clinically, particularly for supraphysiologic dosing regimens.
Considering NAD+ optimization?
Dr. Turner reviews your goals, labs, and risk profile, and gives you a direct, evidence-graded answer on whether oral NR, oral NMN, or IV NAD+ makes sense for your situation — including an honest look at where the outcome evidence is still missing.
Book a ConsultationCall 404.900.7371 · info@pravida.com
Frequently Asked Questions
Does IV NAD+ actually work better than oral NMN or NR?
Not by any measure we can currently point to. The only published human pharmacokinetic study of IV NAD+ showed plasma levels rose sharply during the infusion itself, but there are zero randomized controlled trials showing IV NAD+ improves any clinical outcome — energy, cognition, function, or aging biomarkers — versus placebo. Oral NR, by contrast, has multiple RCTs demonstrating dose-dependent NAD+ increases, and at least one trial testing a functional outcome (six-minute walk distance) that did not separate from placebo. Both routes raise a surrogate marker. Neither route has strong outcome evidence yet, but oral NR has more total human data behind it.
Is NMN legal again in the US?
Yes, as of late 2025. The FDA had excluded NMN from the dietary supplement definition in November 2022 after a pharmaceutical company's investigational new drug application, which created years of regulatory limbo. The FDA reversed that determination on September 29, 2025 following a lawsuit and citizen petition from the Natural Products Association, and issued confirmation letters reinstating NDI status to ingredient manufacturers in December 2025. NMN is again lawful to sell and purchase as a dietary supplement in the United States as of this writing.
How long until I feel a difference from oral NR or NMN?
Blood NAD+ levels rise measurably within one to two weeks of consistent oral dosing in the published trials, but a rising number on a lab panel is not the same as a subjective sense of more energy or better cognition, and most trials did not find that subjective symptoms tracked reliably with the biomarker change. If you try an oral precursor, I would plan on an eight-to-twelve week trial with a clear, pre-specified outcome you are tracking — sleep, exercise capacity, a validated fatigue scale — rather than expecting a felt effect on a particular day.
Should someone with cancer or a history of cancer use NAD+ precursors?
This deserves an individualized conversation with your oncology team before starting anything, and I say that deliberately rather than as a blanket yes or no. NAD+ supports fundamental cellular metabolism and proliferation pathways in all cells, including malignant ones, and the long-term safety data in patients with active or prior cancer is not established for any NAD+-raising strategy, oral or IV. I do not recommend NAD+ precursors or infusions in patients with active malignancy outside of a supervised research protocol, and in patients with a cancer history I want oncology input before considering it.
Does Pravida Health offer NAD+ IV infusions?
We discuss NAD+ optimization as part of our longevity programs and will review your goals, labs, and risk profile honestly, including the fact that IV NAD+ has no outcome trials behind it. For most patients asking about fatigue, brain fog, or general anti-aging goals, we start with studied oral precursor dosing and the foundational levers that influence NAD+ biology before considering an infusion. If you have a specific clinical rationale and have not responded to oral precursors, that is a conversation worth having directly in a consultation.
References
- Grant and colleagues 2019 pilot pharmacokinetic study of a 6-hour IV NAD+ infusion
- Hawkins and Idoine's 2024 real-world pilot comparing commercial NAD+ IV against NR IV
- Orr et al. 2024 NR pilot RCT in older adults with MCI
- Martens et al. 2018 crossover NR trial in healthy middle-aged and older adults
- Dellinger et al. 2017 NRPT double-dose trial in older adults, npj Aging
- NR-SAFE 2023 high-dose nicotinamide riboside trial in Parkinson's disease, Nature Communications
- NICE 2024 peripheral artery disease RCT of NR and resveratrol, Nature Communications
- Kim et al. 2022 oral NMN trial in aged men, npj Aging
- Yamane et al. 2022 12-week NMN safety trial in healthy volunteers, Frontiers in Nutrition
- 2024 NMN systematic review and meta-analysis in Critical Reviews in Food Science and Nutrition
- 2023 NMN safety and anti-aging review, PMC
- Natural Products Association's account of the FDA's 2025 NMN reinstatement
- NutraIngredients' 2025 report on the FDA's NDI status reinstatement for NMN
- 2024 NMN systematic review, PMC